Business Description
Entrada Therapeutics is a Boston-based clinical-stage company developing a new generation of medicines designed to reach targets inside cells that were previously thought to be out of reach. Its pipeline focuses on treatments for neuromuscular and inherited retinal diseases, using a proprietary delivery platform called Endosomal Escape Vehicle technology. Founded in 2016 and formerly operating under the name CycloPorters, the company has built a growing portfolio of drug candidates at both clinical and preclinical stages.
